Skip to main content
. 2023 Nov 23;12(12):2036. doi: 10.3390/antiox12122036

Figure 2.

Figure 2

AKT-1005 treatment reduced systolic BP and mean arterial blood pressure (MAP) in Ad.sFlt-1-injected CD1 pregnant mice and improved plasma NO availability. (a) Pregnant mice given Ad.sFlt-1 on gd8 (induction of disease) and administered either AKT-1005 (n = 10) (20 mg/kg/day) or vehicle (n = 10), starting on gd11 up to gd17. Plasma nitrite concentrations were reduced (Gd17) in Ad.sFlt-1-injected mice and were restored after AKT-1005 treatment. Baseline measurements were taken before treatment with Ad.sFlt-1 in pregnant mice. One-way repeated-measures ANOVA—Gd17: ***: p < 0.001, and *: p < 0.05. (b,c) Pregnant mice were treated as in (a). Systolic BP and MAP are significantly lower in the AKT-1005-treated group (n = 26) compared to the vehicle (n = 22). Two-way repeated-measures ANOVA—Gd14: ****: p < 0.0001, and **: p < 0.01, ns: not significant.